ArticleIndian journal of surgical oncology2026
Trend of Serum CEA in Recurrent Signet Cell Colorectal Adenocarcinomas.
Article in Indian journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) represents a major global health burden, with signet cell adenocarcinoma constituting a rare but aggressive subtype. Despite multimodality treatment with curative intent, recurrence rates remain significant, and outcomes are poor. Carcinoembryonic antigen (CEA) is a widely used biomarker for CRC follow-up; however, its role in signet cell CRC remains inadequately defined. This study aimed to evaluate the trends in serum CEA among baseline CEA secretors and non-secretors presenting with recurrence after curative treatment and assess its value in postoperative surveillance. This retrospective study analyzed data from a prospectively maintained database at a tertiary cancer center between June 2011 and October 2021. Inclusion criteria were patients with recurrent signet cell colorectal adenocarcinoma, treated with curative intent, and with available CEA values at baseline, treatment completion, and recurrence. Variables included demographic data, baseline CEA levels, recurrence patterns, and CEA status at recurrence. Baseline CEA secretors were defined as those with preoperative CEA > 5 ng/ml. Statistical analysis employed chi-square and Fisher's exact tests for categorical data, with significance set at
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.